Aeromics develops AER‑271, an intravenously administered small‑molecule inhibitor of aquaporin‑4 that blocks water influx at the blood‑brain barrier to prevent cerebral edema in acute ischemic stroke. The drug is formulated for rapid infusion in the hyper‑acute window and is currently in a biomarker‑driven Phase II trial targeting large hemispheric infarction, with potential expansion to other neuro‑edema conditions.

Alleviant Medical develops a no-implant shunt therapy designed to alleviate the clinical and economic burden of heart failure. The Alleviant System, which has received Breakthrough Device Designation from the U.S. FDA, aims to improve patient outcomes and reduce healthcare costs associated with heart failure management.

Alveron Pharma was a pharmaceutical company that has ceased all operations as of 30 April 2026 and currently offers no products, services, or active offerings.

Antag Therapeutics is developing first‑in‑class GIP receptor antagonist peptides, such as AT‑7687, to treat obesity, type 2 diabetes, and related metabolic disorders. By blocking the GIP pathway that drives fat storage and insulin resistance, their approach aims to achieve meaningful weight loss and metabolic improvement while preserving lean mass and maintaining tolerability. The lead candidate is in Phase 1a trials as both a monotherapy and in combination with other obesity therapies.

AtaCor Medical develops extravascular cardiac pacing and defibrillation lead systems that eliminate the need for transvenous access, reducing the risks and complications associated with traditional methods. Their technology enables reliable temporary pacing and defibrillation while allowing for safe patient ambulation post-procedure.

Basking Biosciences is developing BB-031, a reversible RNA aptamer designed to target von Willebrand Factor for the treatment of acute ischemic stroke. This therapy aims to provide a rapid-onset, short-acting solution for reopening blocked arteries while allowing for quick neutralization in case of bleeding complications.

Cardiosense is developing a physiological waveform data platform that utilizes multi-sensor wearable devices and proprietary algorithms to detect early markers of cardiac disease. This technology enables continuous patient monitoring and personalized therapy, addressing the need for pre-symptomatic disease detection in cardiac care.

Cella accelerates the natural geologic process of turning carbon dioxide into stable mineral rock for permanent sequestration. The company injects captured atmospheric CO2 into volcanic formations where mineralization securely locks the carbon underground. This technology offers a scalable, verifiable solution for long-term carbon removal storage.

Develops an investigational siRNA-based therapy targeting the root cause of preterm preeclampsia, a life-threatening pregnancy complication. This approach aims to provide safe, evidence-based, and affordable treatment options, improving maternal and neonatal health outcomes globally.

Develops the CoFI System, a medical device that diagnoses microvascular obstruction (MVO) in real-time during percutaneous coronary interventions (PCI) using existing guide catheters and wires. It provides rapid, accurate detection of MVO, a condition affecting up to 60% of acute heart attack patients, and enables controlled delivery of therapeutic agents directly into the vasculature to improve patient outcomes.

Cove is a co‑living platform that offers fully furnished private rooms in curated Singapore properties, with utilities, high‑speed Wi‑Fi, housekeeping and maintenance bundled into a single monthly price. Users can book instantly online for flexible stay lengths—monthly or nightly—and filter listings by location, budget and amenities, while enjoying community events and shared spaces that foster a sense of belonging.

CroíValve is developing the DUO™ Tricuspid Coaptation Valve System, a minimally invasive solution designed for the treatment of severe Tricuspid Regurgitation (TR), which significantly impacts mortality and quality of life in patients over 65. This system uniquely combines repair and replacement techniques to address the specific challenges posed by TR, offering a targeted approach in a growing area of structural heart disease.

Gila Therapeutics is developing a topical lingual signaling platform that utilizes micro-dose PYY to activate the Nucleus Tractus Solitarius, targeting brain areas that regulate food intake and metabolism without entering the bloodstream. This approach aims to provide a safer and more effective treatment for obesity and cardiometabolic disorders, minimizing side effects commonly associated with traditional therapies.

GraftSolutions develops surgical devices that improve coronary artery bypass grafting outcomes. Its VIOLA™ system enables clam‑less proximal aortic anastomosis, eliminating the need for aortic clamps and reducing stroke and delirium risk, while the VEST™ external sleeve reinforces saphenous vein grafts to lower intimal hyperplasia and re‑vascularization rates. Both products are clinically validated and aim to extend graft durability and lower overall care costs for cardiac surgery programs.

HARM provides an AI-powered platform for individuals experiencing harm to quickly access immediate, trusted support. The system intelligently identifies the nature of the reported harm and routes users directly to appropriate, city-approved advocacy, legal, or housing resources. This streamlined process eliminates confusion while generating de-identified data insights to help municipal leaders optimize community support services.

HAYA Therapeutics develops modified antisense oligonucleotides (ASOs) to target and inhibit long non-coding RNAs (lncRNAs) associated with heart failure and other chronic diseases. By focusing on dark genome-derived regulatory RNAs, the company aims to prevent and reverse disease processes in diseased tissues and cells.

Herantis Pharma develops HER-096, a CDNF‑derived peptidomimetic that modulates the unfolded protein response to address proteostasis, mitochondrial dysfunction, and neuroinflammation in Parkinson’s disease. The subcutaneously administered molecule has shown favorable safety, brain penetration, and biomarker activity in Phase 1 trials and is being prepared for a randomized Phase 2 proof‑of‑concept study. The company seeks partnership opportunities to co‑develop or license this disease‑modifying therapy.

The startup develops isoform-specific antibodies that target pathogenic messenger RNA splicing and vascular endothelial growth factor A to enhance blood flow in patients with peripheral arterial disease. This technology provides a treatment option for ischemic diseases where current therapies are limited, facilitating improved vascular health.

Maxwell Biomedical is developing the Spatial Resynchronization Therapy (SRT) System, a non-ablative device that employs ultra-low energy stimulation to restore functional sinus rhythm in patients with atrial fibrillation and heart failure. This technology continuously monitors cardiac activity to prevent AF episodes and improve left atrial function, addressing the increased risks of stroke and heart failure associated with these conditions.

Mosanna Therapeutics is developing a small molecule, MOS-118, specifically targeting metabolic obstructive sleep apnea (MOSA) to enhance patient outcomes. The company aims to improve the quality of life for individuals suffering from this condition by addressing the underlying metabolic factors contributing to their sleep disturbances.

Nido provides an AI-assisted platform for HVAC and renewables professionals to streamline project execution from quoting to installation. The software generates instant 3D plans, electrical/hydraulic diagrams, and branded professional offers, significantly reducing proposal creation time. It also manages project tracking, purchasing, and automates compliance documentation for certifications and subsidies.

NOVA is a platform that connects creative professionals with job opportunities by allowing users to showcase their portfolios and post job listings tailored to specific project needs. It addresses the challenge of finding qualified talent quickly in the creative industry, having generated over $10 million for creatives and facilitated 17,000 job postings across more than 500 cities globally.

Nyra Medical offers the Cardiac Leaflet Enhancer (CARLEN), a transcatheter, single‑leaflet nitinol clip that augments the length and thickness of the mitral valve leaflets to treat functional (secondary) mitral regurgitation. Delivered via a transfemoral, transseptal approach under imaging guidance, CARLEN preserves native valve geometry, is reversible, and expands treatment eligibility for patients who are ineligible for existing edge‑to‑edge repair systems.

Puzzle Medical Devices is developing a minimally invasive long-term hemodynamic transcatheter pump designed to provide cardiac support for patients with chronic heart failure. This technology offers a safer alternative to open-heart surgery, reducing complications and improving patient mobility through its modular design and portable controller.